Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$146.10 ▼ -0.28
(-0.19%)
MKT CAP: $14.88B • VOL: 1.32M
52W L $122 52W H $186
NBIX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.86B | $2.36B | $1.89B |
| YoY Revenue Growth % | +21.4% | +24.8% | — |
| Gross Profit | $2.81B | $2.32B | — |
| Gross Margin % | 98.2% | 98.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $619.1M | $570.5M | $250.9M |
| Operating Margin % | 21.6% | 24.2% | 13.3% |
| Net Income (GAAP) | $478.6M | $341.3M | $249.7M |
| EBITDA (Normalized) | $646.3M | $601.1M | $318.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $782.7M | $595.4M | $389.9M |
| Capital Expenditures (CapEx) | $34.0M | $38.2M | $84.9M |
| Free Cash Flow (FCF) | $748.7M | $557.2M | $305.0M |
| FCF Margin % | 26.2% | 23.7% | 16.2% |
| Return on Invested Capital (ROIC %) | 15.5% | 15.7% | 4.0% |
| Cash & Short-Term Equivalents | $713.0M | $233.0M | — |
| Total Debt (Short + Long Term) | $620.3M | $508.1M | $1.91B |
| Total Stockholders' Equity | $3.25B | $2.59B | $3.93B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NBIX.